Avastin-hcp - avastin-hcp.com : Avastin® (bevacizumab) | Official Healthcare Professional (HCP) Website

2.33 Rating by ClearWebStats

avastin-hcp.com is 1 decade 1 year 5 months old. This website has a #8,777,497 rank in global traffic. It has a .com as an domain extension. This website has a Google PageRank of 4 out of 10. This domain is estimated value of $ 8.95 and has a daily earning of $ 0.15. While no active threats were reported recently by users, avastin-hcp.com is SAFE to browse.

Updated 9 years 10 months ago

Get Custom Widget

Traffic Report of Avastin-hcp

Daily Unique Visitors:	55
Daily Pageviews:	110

Estimated Valuation

Income Per Day:	$ 0.15
Estimated Worth:	$ 8.95

Search Engine Indexes

Google Indexed Pages:	Not Applicable
Yahoo Indexed Pages:	Not Applicable
Bing Indexed Pages:	10

Search Engine Backlinks

Google Backlinks:	Not Applicable
Bing Backlinks:	Not Applicable
Alexa BackLinks:	3

Safety Information

Google Safe Browsing:	No Risk Issues
Siteadvisor Rating:	Not Applicable
WOT Trustworthiness:	Not Applicable
WOT Privacy:	Not Applicable
WOT Child Safety:	Not Applicable

Website Ranks & Scores

Google Pagerank:
Alexa Rank:	8,777,497
Domain Authority:	Not Applicable

Google Pagerank

PR 4 out of 10

PageSpeed Score

Siteadvisor Rating

Not Applicable

Where is avastin-hcp.com server located?

Hosted IP Address:

72.34.128.120

View other site hosted with avastin-hcp.com

Hosted Country:

Location Latitude:

33.1959

Location Longitude:

-117.379

Social Engagement

Facebook Shares:	3
Facebook Likes:	Not Applicable
Facebook Comments:	Not Applicable
Twitter Count (Tweets):	Not Applicable
Linkedin Shares:	Not Applicable
Delicious Shares:	Not Applicable

Page Resources Breakdown

Homepage Links Analysis

View avastin-hcp.com homepage link analysis

Page Title of Avastin-hcp

Avastin® (bevacizumab) | Official Healthcare Professional (HCP) Website

Meta Description of Avastin-hcp

For US HCPs: Access resources for Avastin (bevacizumab) solution for IV infusion, including efficacy data, safety profiles, and information on dosing and usage. Avastin is indicated for the treatment of metastatic renal cell carcinoma in combination with interferon alfa. Avastin is indicated for the treatment of glioblastoma as a single agent for adult patients with progressive disease following prior therapy. The effectiveness of Avastin in glioblastoma is based on an improvement in objective response rate. There are no data demonstrating an improvement in disease-related symptoms or increased survival with Avastin. Avastin is indicated for the first-line treatment of unresectable, locally advanced, recurrent or metastatic non–squamous non–small cell lung cancer in combination with carboplatin and paclitaxel. Avastin is indicated for the first- or second-line treatment of patients with metastatic carcinoma of the colon or rectum in combination with intravenous 5 fluorouracil–based chemotherapy. Avastin, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy, is indicated for the second-line treatment of patients with metastatic colorectal cancer who have progressed on a first-line Avastin-containing regimen. Limitation of Use: Avastin is not indicated for adjuvant treatment of colon cancer. Glioblastoma (GBM) Avastin is indicated for the treatment of glioblastoma as a single agent for adult patients with progressive disease following prior therapy. The effectiveness of Avastin in glioblastoma is based on an improvement in objective response rate. There are no data demonstrating an improvement in disease-related symptoms or increased survival with Avastin. Metastatic colorectal cancer (MCRC) Avastin is indicated for the first- or second-line treatment of patients with metastatic carcinoma of the colon or rectum in combination with intravenous 5-fluorouracil–based chemotherapy. Avastin, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy, is indicated for the second-line treatment of patients with metastatic colorectal cancer who have progressed on a first-line Avastin-containing regimen. Limitation of Use: Avastin is not indicated for adjuvant treatment of colon cancer. Non-squamous non-small cell lung cancer (NSCLC) Avastin is indicated for the first-line treatment of unresectable, locally advanced, recurrent or metastatic non–squamous non–small cell lung cancer in combination with carboplatin and paclitaxel. Metastatic renal cell carcinoma (mRCC) Avastin is indicated for the treatment of metastatic renal cell carcinoma in combination with interferon alfa. BOXED WARNINGS: Gastrointestinal (GI) perforation: Serious and sometimes fatal GI perforation occurs at a higher incidence in Avastin-treated patients compared to controls. The incidences of GI perforation ranged from 0.3% to 2.4% across clinical studies. Discontinue Avastin in patients with GI perforation. Surgery and wound healing complications: The incidence of wound healing and surgical complications, including serious and fatal complications, is increased in Avastin-treated patients. Do not initiate Avastin for at least 28 days after surgery and until the surgical wound is fully healed. The appropriate interval between termination of Avastin and subsequent elective surgery required to reduce the risks of impaired wound healing/wound dehiscence has not been determined. Discontinue Avastin at least 28 days prior to elective surgery and in patients with wound healing complications requiring medical intervention. Hemorrhage: Severe or fatal hemorrhage, including hemoptysis, GI bleeding, hematemesis, central nervous system hemorrhage, epistaxis, and vaginal bleeding, occurred up to 5-fold more frequently in patients receiving Avastin. Across indications, the incidence of grade ≥3 hemorrhagic events among patients receiving Avastin ranged from 1.2% to 4.6%. Do not administer Avastin to patients with serious hemorrhage or recent hemoptysis (≥1/2 tsp of red blood). Discontinue Avastin in patients with serious hemorrhage (ie, requiring medical intervention). ADDITIONAL SERIOUS ADVERSE EVENTS: Additional serious and sometimes fatal adverse events with increased incidence in the Avastin-treated arm vs control included: non-GI fistula formation (≤0.3%), arterial thromboembolic events (grade ≥3, 2.6%), proteinuria (nephrotic syndrome,

Meta Tags of Avastin-hcp

avastin bevacizumab safety, avastin bevacizumab, metastatic colorectal cancer, mcrc, metastatic non squamous non small cell lung cancer, nsclc, recurrent glioblastoma, rgbm, metastatic renal cell carcinoma, mrcc, kidney cancer

Website Inpage Analysis

H1 Headings:	1	H2 Headings:	Not Applicable
H3 Headings:	11	H4 Headings:	Not Applicable
H5 Headings:	11	H6 Headings:	Not Applicable
Total IFRAMEs:	Not Applicable	Total Images:	6
Google Adsense:	Not Applicable	Google Analytics:	Not Applicable

HTTP Header Analysis

Http-Version: 1.1
Status-Code: 200
Status: 200 OK
Date: Tue, 17 Jun 2014 16:53:56 GMT
X-Powered-By: Servlet 2.5; JBoss-5.0/JBossWeb-2.1
Content-Disposition: inline;filename="index.html"
Accept-Ranges: bytes
ETag: /_1399999472788
Last-Modified: Tue, 13 May 2014 16:44:32 GMT
Content-Range: bytes 0-55755/55755
Content-Length: 55755
Keep-Alive: timeout=1, max=80
Connection: close
Content-Type: text/html;charset=UTF-8
Content-Language: en

Domain Information for avastin-hcp.com

Domain Registrar:	CSC CORPORATE DOMAINS, INC.
Registration Date:	2012-10-25 1 decade 1 year 5 months ago
Last Modified:	2014-02-25 1 decade 1 month 3 weeks ago
Expiration Date:	2014-10-25 9 years 6 months 1 day ago

Domain Nameserver Information

Host	IP Address	Country
dnadns2e.gene.com	72.34.128.76	United States
dnadns3e.gene.com	72.34.133.50	United States
dnadns4e.gene.com	72.34.128.50	United States

DNS Record Analysis

Host	Type	TTL	Extra
avastin-hcp.com	A	3587	IP:72.34.128.120
avastin-hcp.com	NS	3600	Target:dnadns4e.gene.com
avastin-hcp.com	NS	3600	Target:dnadns2e.gene.com
avastin-hcp.com	NS	3600	Target:dnadns3e.gene.com
avastin-hcp.com	SOA	3600	MNAME:bc-dns-ext-mstr.gene.com RNAME:postmaster.no.email.please Serial:404592124 Refresh:3600 Retry:600 Expire:2592000